Literature DB >> 11382538

Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls.

R M Steel1, M E Bastin, S McConnell, I Marshall, D G Cunningham-Owens, S M Lawrie, E C Johnstone, J J Best.   

Abstract

Several proton magnetic resonance spectroscopy (1H MRS) studies in schizophrenia have found reduced N-acetyl aspartate (NAA) concentrations in pre-frontal and temporal regions of the brain. Reductions in NAA may reflect abnormalities of neuronal structure (e.g. reduced neuronal density or viability) or abnormalities of neuronal function. Diffusion tensor imaging (DTI) measures diffusion anisotropy, an indicator of the structural integrity of a neuronal tract. Both techniques were used to examine the anatomical basis of pre-frontal dysfunction in schizophrenia. Ten patients with DSM-IV schizophrenia were compared with 10 healthy controls. 1H MRS and DTI were performed on a clinical MR system and analysed with a region of interest approach. NAA concentrations and diffusion anisotropy were measured in the same pre-frontal white matter region. Diffusion anisotropy was also measured in a control region (occipital white matter). 1H MRS revealed non-significant but consistently reduced NAA concentrations (by 10-15%) in the pre-frontal white matter in schizophrenic subjects. Diffusion anisotropy measures revealed no such differences between schizophrenics and controls. It is concluded that the abnormalities of 'connectivity' reported in brain-imaging studies of schizophrenia may not be attributable to structural abnormalities of white matter and that reduced NAA in the pre-frontal white matter may reflect abnormal function of structurally intact neurons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11382538     DOI: 10.1016/s0925-4927(01)00080-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  37 in total

Review 1.  Diffusion tensor imaging and its application to neuropsychiatric disorders.

Authors:  Marek Kubicki; Carl-Fredrik Westin; Stephan E Maier; Hatsuho Mamata; Melissa Frumin; Hal Ersner-Hershfield; Ron Kikinis; Ferenc A Jolesz; Robert McCarley; Martha E Shenton
Journal:  Harv Rev Psychiatry       Date:  2002 Nov-Dec       Impact factor: 3.732

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

3.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

Review 4.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 5.  The application of DTI to investigate white matter abnormalities in schizophrenia.

Authors:  Marek Kubicki; Carl-Fredrik Westin; Robert W McCarley; Martha E Shenton
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

Review 6.  Testing models of thalamic dysfunction in schizophrenia using neuroimaging.

Authors:  K Sim; T Cullen; D Ongur; S Heckers
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

7.  Functional connectivity in fMRI: A modeling approach for estimation and for relating to local circuits.

Authors:  Ransom Winder; Carlos R Cortes; James A Reggia; M-A Tagamets
Journal:  Neuroimage       Date:  2006-11-28       Impact factor: 6.556

8.  Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia.

Authors:  Robert E McCullumsmith; Daya Gupta; Monica Beneyto; Emily Kreger; Vahram Haroutunian; Kenneth L Davis; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2007-01-12       Impact factor: 4.939

9.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

10.  Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia.

Authors:  Subroto Ghose; Jeremy M Crook; Cynthia L Bartus; Thomas G Sherman; Mary M Herman; Thomas M Hyde; Joel E Kleinman; Mayada Akil
Journal:  Int J Neurosci       Date:  2008-11       Impact factor: 2.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.